Microbot Medical Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Microbot Medical Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $29.0K | Mar 15, 2016 |
| FY2015 | Sep 30, 2015 | $37.0K | Mar 15, 2016 |
| FY2015 | Jun 30, 2015 | $30.0K | Mar 15, 2016 |
| FY2015 | Mar 31, 2015 | $21.0K | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $883.0K | Mar 15, 2016 |
| FY2015 | Nov 30, 2014 | $1.01M | Mar 15, 2016 |
| FY2015 | Sep 30, 2014 | $82.0K | Mar 15, 2016 |
| FY2015 | Jun 30, 2014 | $23.0K | Mar 15, 2016 |
| FY2015 | Mar 31, 2014 | $24.0K | Mar 15, 2016 |
| FY2014 | Dec 31, 2013 | $45.0K | Mar 13, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $886.6K | Mar 13, 2014 |
| FY2013 | Dec 31, 2012 | $1.10M | Mar 13, 2014 |
| FY2013 | Dec 31, 2011 | $1.01M | Mar 13, 2014 |
| FY2012 | Dec 31, 2010 | $1.26M | Mar 21, 2013 |
| FY2011 | Dec 31, 2009 | $731.4K | Mar 15, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.14M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.44M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($10.74M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($13.17M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($11.31M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.17M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($7.25M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($7.26M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($7.59M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($9.66M) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.74M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($11.63M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($9.86M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($13.28M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($11.36M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($9.09M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($7.24M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($7.24M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $5.27M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($9.64M) | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.28M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.63M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.72M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $7.74M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $6.15M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $3.40M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $3.05M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.52M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.10M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($901.0K) | Apr 2, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.46M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.00M | Mar 26, 2026 |
| FY2014 | Dec 31, 2014 | $10.42M | Mar 13, 2015 |
| FY2014 | Dec 31, 2013 | $8.83M | Mar 13, 2015 |
| FY2014 | Dec 31, 2012 | $7.36M | Mar 13, 2015 |
| FY2013 | Dec 31, 2011 | $8.20M | Mar 13, 2014 |
| FY2012 | Dec 31, 2010 | $9.38M | Mar 21, 2013 |
| FY2011 | Dec 31, 2009 | $9.53M | Mar 15, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.05M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.83M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($8.53M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($11.55M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($9.35M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($7.25M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($6.45M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.31M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($4.86M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($786.0K) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $25.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $33.0K | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $84.0K | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $69.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $91.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $216.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $223.0K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $58.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $25.0K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.54M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.03M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.33M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $9.54M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $16.77M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $26.28M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $37.13M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.09M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $11.02M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $3.37M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.99M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.50M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $3.83M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.25M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $2.39M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.59M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $4.76M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $556.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.17M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.55M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.53M | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.50M | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $7.29M | Mar 25, 2025 |
| FY2023 | Dec 31, 2021 | $14.38M | Mar 27, 2024 |
| FY2022 | Dec 31, 2020 | $24.31M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $31.54M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.33M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $9.99M | Apr 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.70M | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2014 | Dec 31, 2013 | $2.14M | Mar 13, 2015 |
| FY2013 | Dec 31, 2012 | $1.98M | Mar 13, 2014 |
| FY2012 | Dec 31, 2011 | $1.90M | Mar 21, 2013 |
| FY2011 | Dec 31, 2010 | $1.88M | Mar 15, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($104.09M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($90.94M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($79.50M) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | ($68.76M) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | ($55.59M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($44.28M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($35.11M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($27.86M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($20.62M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($13.04M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.91M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.11M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.47M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | $2.44M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | $13.49M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $19.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $28.77M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.24M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $10.79M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.71M | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 27, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 67.16M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 19.40M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 11.71M | Mar 25, 2025 |
| FY2023 | Dec 31, 2022 | 7.89M | Mar 27, 2024 |
| FY2022 | Dec 31, 2021 | 7.11M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 7.11M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 7.19M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 3.01M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | 2.01M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 15.85M | Apr 2, 2018 |